Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
0.965
-0.007 (-0.68%)
At close: Nov 4, 2024, 4:00 PM
1.020
+0.055 (5.72%)
Pre-market: Nov 5, 2024, 4:50 AM EST

Company Description

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.

Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia.

The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program. Scilex Holding Company is headquartered in Palo Alto, California.

Scilex Holding Company
Scilex Holding Company logo
Country United States
Founded 2011
Industry Drug Manufacturers - General
Sector Healthcare
Employees 105
CEO Jaisim Shah

Contact Details

Address:
960 San Antonio Road
Palo Alto, California 94303
United States
Phone 650 516 4310
Website scilexholding.com

Stock Details

Ticker Symbol SCLX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001820190
CUSIP Number 80880W106
ISIN Number US80880W1062
SIC Code 2836

Key Executives

Name Position
Jaisim Shah President, Chief Executive Officer and Director
Dr. Henry H. Ji Ph.D. Executive Chairman
Stephen Ma Senior Vice President, Chief Financial Officer and Corporate Secretary
Dr. Suketu D. Desai Ph.D. Chief Technology Officer and Senior Vice President
Steven F. Lincoln J.D. General Counsel and Chief Compliance Officer
Sumant Rajendran Executive Director of Marketing
Mike Ciaffi National Sales Director
Suresh K. Khemani Senior Vice President and Chief Commercial Officer
Dr. Dmitri V. Lissin M.D. Senior Vice President and Chief Medical Officer
Gigi DeGuzman Senior Executive Director and Chief of Staff

Latest SEC Filings

Date Type Title
Oct 28, 2024 424B3 Prospectus
Oct 28, 2024 424B3 Prospectus
Oct 28, 2024 8-K Current Report
Oct 8, 2024 424B3 Prospectus
Oct 8, 2024 424B3 Prospectus
Oct 8, 2024 8-K Current Report
Oct 8, 2024 8-K Current Report
Oct 8, 2024 424B3 Prospectus
Oct 8, 2024 424B3 Prospectus
Oct 7, 2024 8-K Current Report